Objective: We determined the role of the neurosteroid-sensitive d subunit-containing c-aminobutyric acid A receptors (d-GABARs) in epileptogenesis. Methods: Status epilepticus (SE) was induced via lithium pilocarpine in adult rats, and seizures were assessed by continuous video-electroencephalography (EEG) monitoring. Finasteride was administered to inhibit neurosteroid synthesis. The total and surface protein expression of hippocampal d, a4, and c2 GABAR subunits was studied using biotinylation assays and Western blotting. Neurosteroid potentiation of the tonic currents of dentate granule cells (DGCs) was measured by whole-cell patchclamp technique. Finally, the effects of inhibiting N-methyl-D-aspartate receptors (NMDARs) during SE on the long-term plasticity of d-GABARs, neurosteroid-induced modulation of tonic current, and epileptogenesis were studied. Results: The inhibition of neurosteroid synthesis 4 days after SE triggered acute seizures and accelerated the onset of chronic recurrent spontaneous seizures (epilepsy). The down-regulation of neurosteroid-sensitive d-GABARs occurred prior to the onset of epilepsy, whereas an increased expression of the c2-GABAR subunits occurred after seizure onset. MK801 blockade of NMDARs during SE preserved the expression of neurosteroid-sensitive d-GABARs. NMDAR blockade during SE also prevented the onset of spontaneous seizures. Significance: Changes in neurosteroid-sensitive d-GABAR expression correlated temporally with epileptogenesis. These findings raise the possibility that d-GABAR plasticity may play a role in epileptogenesis.
Acquired epilepsy often results from brain insults such as febrile seizures, status epilepticus (SE), brain tumors, infection, or head trauma. The initial brain insult is followed by a latent period of variable length before the appearance of spontaneous seizures. Changes that occur during this period due to neuronal plasticity underlie epileptogenesis, the process that transforms a normal brain into one that can initiate and sustain seizures. A recent study found that impaired neurosteroidogenesis is associated with protocadherin 19 (PCDH19) female-limited epilepsy, 1 suggesting that endogenous neurosteroids may play a role in epileptogenesis. Another study in experimental animals found accelerated epileptogenesis when endogenous neurosteroid synthesis was blocked by daily treatment with finasteride. 2 These studies did not elucidate the mechanism of neurosteroid modulation involved in epileptogenesis.
Temporal lobe epilepsy (TLE) is a common form of acquired epilepsy that primarily affects the hippocampus. Reduced c-aminobutyric acid (GABAR)-mediated inhibition of hippocampal dentate granule cells (DGCs) is thought to play an important role in epileptogenesis. A prominent alteration in GABARs is the down-regulation of d subunitcontaining GABAR expression.
3-5 A prior study found reduced d-subunit expression before the onset of epilepsy 3 ; however, the functional significance of the early down-regulation of d-GABAR expression was not assessed. d-GABARs are a preferred target of neurosteroids, which are the endogenous ligands of GABARs, at physiologic concentrations. 6 Neurosteroids, synthesized from cholesterol or derived from circulating steroid hormones in the brain, exert anticonvulsant effects to regulate seizure frequency in epileptic animals and play a central role in catamenial seizure exacerbation. 6, 7 d-GABARs are localized to the perisynaptic and extrasynaptic membrane of DGCs and mediate a steady background current called tonic inhibition, which regulates network excitability. 6 Multiple studies have shown a strong correlation between neurosteroid levels, d-GABAR expression, and seizure susceptibility. [8] [9] [10] We determined the time course of the changes in neurosteroid modulation of d-GABAR during epileptogenesis. These receptors are down-regulated a few days after SE; the seizure activity began one or more weeks following SE. Blocking endogenous neurosteroid synthesis accelerated the onset of seizures, whereas N-methyl-D-aspartate receptor (NMDAR) antagonist treatment during SE prevented d-GABAR down-regulation and suppressed epileptogenesis.
Materials and Methods
The animals were handled according to guidelines set by the University of Virginia Animal Care and Use Committee, and efforts were made to minimize animal stress and discomfort. All the drugs were administered intraperitoneally.
Study design
The time course of diminished neurosteroid sensitivity of tonic inhibition of DGCs and d-GABAR down-regulation was compared to that of a4 and c2 subunits and to the onset of recurrent spontaneous seizures. Neurosteroid synthesis was inhibited during the early latent period, and the onset of epilepsy was determined. Finally, we studied the impact of NMDAR antagonists administered during the established phase of SE on d-GABAR expression and epileptogenesis.
Electroencephalography (EEG) recording
The implantation of bipolar hippocampal and cortical electrodes and video-EEG recordings were performed as described previously.
11
Induction of SE and TLE Adult female and male Sprague-Dawley rats (200-250 g) obtained from Taconic were used in these studies. SE was induced in using the lithium-pilocarpine method. 11 Only animals that experienced prolonged (6-7 h) electrographic SE characterized by rhythmic spike-wave discharges with a frequency >2 Hz and an amplitude that was three times the background amplitude, were included in the study. The end of SE was characterized by arrhythmic spike-wave discharges <3 Hz without the subsequent return of seizures. The animals were considered epileptic after the second spontaneous electrographic seizure.
Finasteride treatment
Animals used in these studies were treated with diazepam (10 mg/kg) 2 h after the start of continuous electrographic seizures. Diazepam suppressed behavioral seizures, but electrographic seizures continued in all the animals; the average duration of SE was 478 (mean) AE (standard error) 36 min (n = 16). The animals were monitored continuously (24/7) by recording video-EEG during SE and for the subsequent 20 days. Finasteride (100 mg/kg) or vehicle (30% cyclodextrin) was administered on the fourth day following SE.
NMDAR antagonist treatment
Continuous seizure activity evolved 21 AE 2 min (n = 8) after pilocarpine administration; this also corresponded to the first tonic-clonic seizure as determined based on the Racine scale. 12 Animals were treated with dizocilpine (MK-801, 2 mg/kg) or saline 10 min after the onset of continuous electrographic seizure activity.
The animals used in the biochemical and electrophysiologic studies were visually monitored for behavioral seizures following pilocarpine administration. The drugs were administered 10 min after the first behavioral stage 5 seizure was observed.
Brain slicing and electrophysiology
To determine the neurosteroid modulation of tonic currents, brain slicing and whole-cell patch-clamp recordings were performed as described previously. 4 Tonic currents were analyzed as described previously. protein fractions were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Expression of the d, a4, and c2 subunits was detected by Western blotting. The antibodies used were an anti-d subunit antibody (1:1,000; Millipore, Billerica, MA, U.S.A.), an anti-a4 subunit (1:500; Millipore), an anti-c2 subunit antibody (1:500), 13 and an anti-b-actin antibody (1:5,000; SigmaAldrich Corporation).
Real-time polymerase chain reaction (PCR)
Total RNA was isolated using Trizol reagent (Invitrogen), and the quality of the messenger RNA (mRNA) was confirmed using an Agilent Bioanalyzer. RNA was treated with RNase-free DNase (New England Biolabs), and 1 lg of RNA was converted to complementary DNA (cDNA) using an iScript cDNA synthesis kit according to the manufacturer's instructions (BioRad). The PCR mix consisted of SYBR green dye (Bioline), 1 lM of each primer, and 1 ll of cDNA template. The PCR was carried out using a QiaABI Prism 7900 HT Detection system (Applied Biosystems). The following primers were used: d subunit (NM_017289), GCCATGTCCTGGGTCTCCTT and TAACCATGAGTG TGGTCATTGTCA; c2 subunit (NM_183327), TTTGTG AGCAACCGGAAACC and TCATTTGGATCGTTGCT GATCT; a4 subunit (NM_080587), ACACTGCAGCCA GCTCCTTT and CAGGCACCCCTGTCGTATTAAC; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (NM_017008), CATGGCCTTCCGTGTTCCTA and CTT CACCACCTTCTTGATGTCATC, which was used for normalization. All primers spanned an intron and amplified a 99-bp fragment. The PCR cycle consisted of denaturation for 10 min at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Each sample was run in triplicate. The change in the cycle threshold value (C T ) in experimental animals relative to that in controls was determined (DDC T method). 14 
Statistical analysis
The results are presented as the means AE standard error of the mean (SEM). The data were compared using Student's t-test, Wilcoxon signed-rank test, or one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison post hoc test. Differences in the time course of onset of epilepsy were compared using Kaplan-Meier survival estimation followed by log-rank (Mantel-Cox) test.
Results

Blockade of endogenous neurosteroid synthesis accelerated epileptogenesis
In a previous study, using video monitoring only, it was suggested that chronic blockade of neurosteroid synthesis accelerates epileptogenesis. 2 We tested whether a single day of inhibition of neurosteroid synthesis with finasteride would be sufficient to accelerate the development of epilepsy, as monitored by EEG and video. Animals implanted with cortical and hippocampal electrodes underwent SE and were monitored continuously by video-EEG until at least the occurrence of a second spontaneous seizure (epilepsy onset).
On the fourth day following SE, seizure-free female animals were randomly divided into two groups: eight animals received finasteride (100 mg/kg), which blocks endogenous neurosteroid synthesis by inhibiting enzyme 5a-reductase, whereas eight animals served as the controls. Among the controls, three animals received the vehicle (30% cyclodextrin), and five animals were left untreated. The effect of finasteride was evident in the form of an increased frequency of spikes within 60 min; six (62%) of eight animals experienced seizures during the first 24 h following finasteride treatment, and one animal had paroxysmal epileptiform discharges ( Fig. 1A-C) . In contrast, none of the control animals (vehicle-treated or untreated post-SE animals) experienced seizures over this time frame (n = 8, p < 0.05 Fisher's exact test, Fig. 1A ,C). Consistent with the findings of other reports, non-SE animals treated with finasteride (n = 3) did not have seizures. 7, 15 To test whether the blockade of endogenous neurosteroid synthesis accelerated epileptogenesis, we continued to monitor the animals. The time to the second spontaneous seizure (onset of epilepsy) was determined using video-EEG monitoring of each animal, and the percentage of animals that became epileptic was plotted using a Kaplan-Meier survival estimator. The acute effects of finasteride wear off by 18-20 h 7 ; therefore, only seizures that occurred 24 h after finasteride administration were considered to be "spontaneous." Finasteride-treated animals continued to experience seizures (Fig. 1D) . Two (25%) of the eight finasteride-treated animals experienced at least two seizures (onset of epilepsy), which typically lasted 40-50 s, on the fifth day following SE. Half of the finasteride-treated animals were epileptic on the sixth day following SE, whereas in control animals this occurred on day 11 (Fig. 1D , p < 0.01, logrank test). The time for the onset of epilepsy in control animals ranged from 7 to 18 days (n = 8, Fig. 1D ). One finasteride-treated and one control animal did not develop epilepsy during the 20 days of continuous video-EEG monitoring. Thus finasteride-treated animals developed epilepsy sooner than controls did.
d-GABAR expression was reduced before the onset of epilepsy
We determined whether the expression of the d subunit is diminished following SE and prior to the onset of recurrent spontaneous seizures because changes in GABARs occurring during this period may contribute to epileptogenesis.
The mRNA expression of the d subunit in the hippocampi of female animals 7 days post-SE (7-SE) was determined using real-time PCR, and it was lower than that in the agematched controls ( Fig. 2A) . The protein expression of the d subunit was also reduced in the hippocampi of 7-SE female animals ( Fig. 2B , 68 AE 8% of that in na€ ıve animals, n = 6, p < 0.05, Wilcoxon signed-rank test). Because surfaceexpressed receptors are physiologically active, we used a biotinylation assay to assess surface-expressed d subunits. The surface expression of the d subunit protein in the hippocampi of 7-SE female animals was also less than that in the naive animals processed in parallel (Fig. 2B,C) . The ratio of surface to total d subunit expression was 0.12 AE 0.03 in 7-SE animals and 0.23 AE 0.04 in naive animals (n = 6, p < 0.05, t-test). The surface to total expression of d-GABARs was also reduced in male 7-SE animals (7-SE; 0.34 AE 0.06 vs. naive: 0.64 AE 0.06, n = 6, p < 0.005, t-test).
Neurosteroid-induced modulation of tonic current of DGCs was diminished in 7-SE animals
The reduced d-GABAR expression in the hippocampi of 7-SE animals suggests that the neurosteroid sensitivity of the tonic current recorded from DGCs was diminished. dGABARs are a major target of neurosteroids at physiologic concentrations, and their expression level correlates with the neurosteroid sensitivity of extrasynaptic GABARmediated inhibition. 4, 9 We recorded tonic currents from DGCs using whole-cell patch-clamp electrophysiologic techniques. 4 The application of allopregnanolone (10 nM) increased the (I hold ), which is a typical measure of extrasynaptic GABAR current 16 of DGCs from naive male animals (Fig. 3A) . In contrast, allopregnanolone did not increase the I hold of DGCs from 7-SE animals (Fig. 3A) . Furthermore, a higher concentration of allopregnanolone (30 nM) only marginally increased the holding current (I hold ) of DGCs from 7-SE male animals (Fig. 3B) . Allopregnanolone modulation of I hold was also reduced in 7-SE female animals. Naive female animals in estrus and metestrus stages were used to avoid the influence of the endogenous rise in progesterone that occurs during proestrus and diestrus phases of the estrus cycle. 17 Allopregnanolone (30 nM)-DI hold in DGCs of these animals was 7.6 AE 1 pA (n = 6 cells/4 animals), larger than DI hold in DGCs of 7-SE animals (3 AE 0.7 pA, n = 8 cells/5 animals, p < 0.005, t-test).
The reduced expression of functional d-GABARs was further confirmed by determining the effect of DS2 (4-chloro-N-[2-(2-thienyl)imidazo [1,2-a]pyridin-3-yl]benzamide), a a4bxd-GABAR-selective allosteric modulator, 18 on I hold . A bath application of 100 nM and 300 nM DS2 enhanced the I hold of DGCs from naive male animals in a concentration-dependent manner (Fig. 3C) . In contrast, neither concentration of DS2 altered the I hold of DGCs from 7-SE male animals (Fig. 3C,D) . Next, we determined the time course of the reduction in surface d-GABAR expression. The surface expression of dGABARs was diminished in 4-SE female animals, and it remained diminished 1, 3, and 6 weeks after SE, whereas spontaneous seizures continued (Fig. 2C) . Thus in the 7-SE animals, the expression of d-GABARs was reduced and the neurosteroid modulation of tonic current of DGCs was also diminished. The reduction in the d-GABAR expression persisted in the epileptic animals. Spontaneous seizures began after d-GABAR down-regulation.
The expression of a4 and c2 subunits in 7-SE animals
The expression of a4 and c2 subunits of GABARs is increased in the DGCs of epileptic animals, whereas the assembly of a4 and c2 subunits is increased as early as 24 h post-SE. 4, 19, 20 The d subunits assemble with the a4 subunits to form receptors targeted to the extrasynaptic membrane. 6 We determined whether the reduction in the expression of the d subunit was independent of the plasticity of the a4 and c2 subunits in female animals. Unlike the pattern for the d subunit, the mRNA expression of the a4 and c2 subunits in 7-SE animals was similar to that in naive animals ( Fig. 2A) . The protein expression of a4 and c2 subunits was also not different between 7-SE and naive animals (Fig. 2B , 83 AE 8%, n = 5, p > 0.05 and 79 AE 28%, n = 7, p > 0.05). The surface expression of these subunits was also unchanged; the surface-to-total expression ratio for a4 subunits in 7-SE animals was 0.27 AE 0.13, similar to that in naive animals (0.22 AE 0.07, n = 5, p > 0.05, Fig. 2B ). The surface-to-total ratio for c2 subunit expression in 7-SE animals was also unchanged (0.43 AE 0.13 in 7-SE animals and 0.51 AE 0.2 in controls, n = 6, p > 0.05, t-test).
Next, we determined the time course of changes in the expression of c2-GABAR expression following SE. The surface expression of c2-GABAR was increased in 14-SE female animals, and it remained high at subsequent time points (Fig. 2C) . Thus, d-GABARs were down-regulated prior to the start of spontaneous seizures, whereas the upregulation of c2-GABARs appeared to coincide with the onset of epilepsy (Fig. 2C) .
Blocking NMDA receptors (NMDARs) during SE prevented the down-regulation of d-GABAR expression and suppressed epileptogenesis Neurosteroid signaling was altered and d-GABAR expression was reduced before the onset of epilepsy, suggesting a temporal correlation. We then determined whether preventing d-GABAR down-regulation could suppress epileptogenesis. Studies in cultured hippocampal neurons have revealed that NMDAR activation reduces d subunit expression. 21 NMDARs are activated during SE 22 ; therefore, we determined whether blocking NMDARs could maintain d subunit expression. , and c2 GABAR subunits in the hippocampi of 7-SE (red) animals compared to that in naive animals (black). The mRNA levels were determined using real-time PCR. The C T for GABAR subunits was normalized to the C T of GAPDH, which was used as an internal control. The relative mRNA expression in 7-SE animals was calculated using the DDC T method (N = 6 for each, **p < 0.05). (B) Representative Western blots of the surface (panel surf) and total (panel input) expression of the d subunit of GABARs in hippocampal proteins isolated from naive (C) and 7-SE animals. The expression of the a4 and c2 subunits was also determined in the same samples as the control. The expression of b-actin was used as a loading control for total protein content. Arrows indicate signals corresponding to each subunit. (C) The time-course of the reduction in the surface expression of d-GABARs following SE relative to that in naive animals. Values represent means AE SEMs in this and subsequent figures (N = 6 animals each at 4, 7, and 14 days post-SE, 4 animals at 21 days post-SE, and 5 at 30+ days post-SE, *p < 0.05, **p < 0.001). The changes in the surface expression of c2-GABARs during epileptogenesis were also determined (N = 5 animals at 4 days post-SE, 6 animals at 7 days post-SE, 7 animals at 14 days post-SE, 4 animals at 21 days post-SE, and 7 at 30+ days post-SE animals, *p < 0.05, **p < 0.001). The pink area illustrates the onset of epilepsy determined in a separate cohort of animals (see Fig. 1D for details) .
We treated animals with MK-801 (2 mg/kg) 10 min after the start of continuous electrographic seizures; this dose was selected because it does not affect SE. 23 Because the duration of SE affects the length of the latent period, we first confirmed that treatment with the NMDAR antagonist did not shorten SE (Fig. 4A) . The termination of SE was defined as the frequency of spike-wave discharges being reduced to below 3 Hz and becoming arrhythmic and no occurrence of seizures for 60 min. In the control animals, seizures lasted for 445 AE 121 min (Fig. 4A , n = 12, male and female animals pooled together). SE also continued unabated in MK-801-treated male and female animals pooled together (599 AE 45, n = 8). Thus, the blockade of NMDARs during SE did not lead to an early termination of SE.
We also analyzed EEG recordings for other changes beyond visually apparent seizures by performing a power analysis. The power of the EEG studies remained high for 3 h following the start of continuous seizures in the untreated animals (Fig. 4B) . However, the power of EEG findings, particularly in the d and h frequencies, was reduced in MK-801-treated animals (Fig. 4B) . There was also a substantial reduction in the EEG power in MK-801-treated animals after 1.5 h.
Then, we determined the surface expression of dGABARs 7 days following SE. The surface expression of d-GABARs in the hippocampi of MK801-treated 7-SE female animals was similar to that in naive female animals (Fig. 5A,B) . Furthermore, the d subunit mRNA levels were also comparable between MK-801-treated and naive female animals (Fig. 5C) .
We determined whether the neurosteroid-induced modulation of tonic current of DGCs was also maintained in NMDAR-antagonist-treated animals (Fig. 5D,E) . In accordance with the preserved surface expression of dGABARs, the application of allopregnanolone (30 nM) potentiated the tonic current of DGCs in the MK-801-treated 7-SE male animals, similar to the effects observed in the DGCs of naive male animals (Fig. 5D,E) . MK-801 The DS2-induced DI hold (for 100 nM DS2 N = 7 DGCs from five control animals and 5 DGCs from five 7-SE animals, and for 300 nM DS2 N = 4 DGCs from four control animals and six DGCs from six 7-SE animals, *p < 0.05). Epilepsia ILAE treatment also preserved neurosteroid modulation of tonic current in the female 7-SE animals; allopregnanolone (30 nM)-DI hold in MK-801-treated 7-SE animals was 5.8 AE 0.5 pA (n = 6 cells from four animals), similar to that in the controls (7.6 AE 1 pA, n = 6 cells/4 animals, p > 0.05).
NMDAR blockade during SE suppressed epileptogenesis
NMDAR blockade during SE maintained d-GABAR expression and preserved the neurosteroid modulation of tonic current. This suggests that epileptogenesis may be suppressed in MK-801-treated animals. To test this, male and female animals were monitored continuously by video-EEG for 30 days following SE. The time to second spontaneous seizure was noted in each animal, and the percentages of animals that became epileptic were plotted. Epilepsy onset occurred between 7 and 14 days following SE in the untreated or diazepam-treated animals (Fig. 5F ). In contrast, none of the MK-801-treated animals developed epilepsy during the 30-day monitoring period (Fig. 5F , p < 0.001, Kaplan-Meier survival estimator followed by signed log-rank test). Thus, the blockade of NMDARs during SE also suppresses the development of epilepsy.
Discussion
This study demonstrates that the down-regulation of neurosteroid-sensitive d-GABARs occurs before the onset of epilepsy; however, the up-regulation of c2-GABARs, which may partially compensate for the reduction in d-GABAR expression, follows onset of spontaneous seizures. This delay could contribute to the transient impairment of the dentate gating function observed following SE. 24 The impairment of gating function was also evident in the finasteride experiments, in which blocking endogenous neurosteroid synthesis accelerated the onset of recurrent spontaneous seizures. The finasteride acceleration of epileptogenesis was also reported in another study, 2 where the drug was administered daily between 3 and 18 days following SE. In contrast, the current study found that a single injection of finasteride administered at the time of the downregulation of d-GABAR expression hastened the onset of epilepsy.
This study describes precisely the temporal relationship between down-regulation of d-GABARs and up-regulation of c2 subunits and onset of epilepsy. The SE-induced alterations in the d, a4, and c2 subunit-containing receptors followed distinct time courses in relation to the process of epileptogenesis. Similar alterations in GABAR subunit expression were also observed in a mouse model of epileptogenesis using immunohistochemistry, 3 but in that study, seizures were monitored by video alone, which may have missed nonconvulsive seizures. 25 In contrast to the findings of this study, in a prior study using a singlecell RNA amplification a4 subunit, mRNA expression in DGCs was reduced 1 day following SE, whereas in another study, a4 subunit protein was reduced in CA1 neurons of 4 and 8 days post-SE animals. 26, 27 In addition, SE also induces alterations in the subunit assembly; in a prior study, increased assembly of a4c2 subunits was seen in the DGCs as early as 24 h post-SE. 19 The reasons for the discrepant findings are unclear; differences in the methods of quantification and in the regions that were used could account for some of the distinctions. The current studies were performed using mRNA or protein isolated from whole hippocampi, whereas prior studies used either microdissected DG or CA1 areas.
NMDAR activation during SE may play a role in the plasticity of d-GABARs following SE. NMDAR activation triggers the down-regulation of d subunit expression in cultured hippocampal neurons, and inhibition of ERK1/2 activation prevented the NMDA-induced reduction in d subunit expression. 21 NMDAR blockade during SE preserved d subunit expression. This action of NMDAR blocker may be specifically related to receptor blockade or may relate to nonspecific actions on the neuronal dynamics during SE. NMDAR antagonists are known to affect EEG regardless of their ability to terminate SE. 28 Indeed, in the current study, the power of EEG Epilepsia ILAE in certain frequencies was different between MK-801-treated and untreated animals. Altered GABAergic transmission is proposed to play an important role in the disinhibition of DGCs during epileptogenesis. 29 The potential mechanisms contributing to the reduced GABAergic inhibition involve a loss of interneurons, the zinc-induced collapse of inhibition, and altered GABAR expression. 6, 30, 31 However, the synaptic events recorded from the DGCs of epileptic animals are larger than those observed in controls, and the sprouting of connections from remaining interneurons has been observed in association with epilepsy, which may compensate for the loss of a fraction of interneurons. 31 Whether the zinc-induced inhibition of GABARs expressed on DGCs can occur in vivo is also unclear. The observed reduction in the expression of neurosteroid-sensitive d-GABAR during epileptogenesis provides a mechanism that may contribute to the disinhibition of DGCs in vivo. Prior studies have also observed a strong correlation between d-GABAR expression, neurosteroid-induced modulation of tonic current, and seizure susceptibility. [8] [9] [10] Prior studies have found antiepileptogenic effect of NMDAR antagonists administered during SE. 32, 33 In this study, NMDAR blockade during SE also suppressed epileptogenesis and prevented d-GABAR down-regulation. However, it is not clear whether the two phenomena are causally related. MK-801 treatment did not affect the duration of SE, which appears to regulate the length of latent period. 34 NMDAR blockade prevents neuronal loss 35, 36 and may reduce the severity of glutamate toxicity that is associated with oxidative stress and inflammation. 37 NMDAR blockade is also likely to reduce calcium influx, which regulates cellular signaling. 38 Thus, the observed antiepileptogenic action of MK-801 could be a combination of multiple factors, which could include d-GABAR down-regulation. Further studies, such as reintroduction of d-GABAR in the hippocampus of epileptic animals combined with video-EEG monitoring, are needed to test the role of these receptors. Similar studies were conducted for the a1 subunit of GABAR. 39 There are other molecular targets for preventing epileptogenesis: signaling proteins such as mammalian target of rapamycin (mTOR), tyrosine receptor kinase B (TrkB), and Janus kinase and Signal Transducer and Activator of Transcription (JAK/STAT), and transcriptional and/or posttranslational regulators such as neuron restrictive silencing factor (NRSF), cyclic AMP response element-binding protein (CREB), and micro RNAs (miRNAs). The blockade of TrkB activation following SE is ant-epileptogenic and prevents neurodegeneration. 40 The infusions of antagomirs targeting miR134 or oligonucleotides preventing the binding of NRSF to its targets, such as HCN1, also suppressed spontaneous seizures. 41, 42 In these studies, the treatments were initiated after SE and performed for a week or longer following SE, which is the entire latent period in rodents. In humans, epileptogenesis is a much slower process, and the seizure-free latent period can last from months to years. Thus, any antiepileptogenic treatment targeting these pathways could require drug treatment for months or years. Few U.S. Food and Drug Administration (FDA)-approved drugs exist to target these signaling systems, and the ones that are approved have toxic side effects, which would be difficult to tolerate if treatments were continued over a prolonged period. In contrast, ketamine has already been used for the treatment of refractory and super-refractory SE. 43, 44 Ketamine has been in clinical use for decades, and recent studies have demonstrated its efficacy in the treatment of benzodiazepine-refractory SE, with few adverse effects. 43, 44 A clinical trial testing therapeutic role of ketamine in the treatment of established SE is feasible, as demonstrated by the ongoing established status epilepticus treatment trial (ESETT). 45 Benzodiazepines are recommended as the initial treatment for convulsive SE in adults and children. This recommendation is based on multiple clinical trials, which also demonstrate that they can be safely administered in the field. [46] [47] [48] [49] Patients who do not respond to benzodiazepines frequently arrive in emergency departments with continued seizure activity, and this benzodiazepine refractory SE is referred to as established status epilepticus. In the lithium/ pilocarpine rodent model of SE, animals initially experience intermittent seizures that progress to continuous electrographic seizure activity. Benzodiazepines effectively terminate intermittent seizure activity in rodents but are ineffective if administered after continuous seizures have evolved in this model. 50, 51 Other findings suggest a role for NMDAR antagonists in treatment of SE. High doses of NMDAR antagonists can terminate experimental SE, and the low doses of these agents can terminate SE in combination with benzodiazepines. 11, 23 In conclusion, this study demonstrates that the expression of d-GABARs is reduced and endogenous neurosteroid signaling is altered during epileptogenesis prior to the onset of seizures.
